Development of thermosensitive poly(n-isopropylacrylamide-co-((2- dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release
Journal
Nanotechnology
Journal Volume
22
Journal Issue
26
Date Issued
2011
Author(s)
Abstract
Thermosensitive nanoparticles based on poly(N-isopropylacrylamide-co-((2- dimethylamino)ethylmethacrylate)) (poly(NIPA-co-DMAEMA)) copolymers were successfully fabricated by free radical polymerization. The lower critical solution temperature (LCST) of the synthesized nanoparticles was 41 °C and a temperature above which would cause the nanoparticles to undergo a volume phase transition from 140 to 100nm, which could result in the expulsion of encapsulated drugs. Therefore, we used the poly(NIPA-co-DMAEMA) nanoparticles as a carrier for the controlled release of a hydrophobic anticancer agent, 7-ethyl-10-hydroxy-camptothecin (SN-38). The encapsulation efficiency and loading content of SN-38-loaded nanoparticles at an SN-38/poly(NIPA-co-DMAEMA) ratio of 1/10 (D/P = 1/10) were about 80% and 6.293%, respectively. Moreover, the release profile of SN-38-loaded nanoparticles revealed that the release rate at 42 °C (above LCST) was higher than that at 37 °C (below LCST), which demonstrated that the release of SN-38 could be controlled by increasing the temperature. The cytotoxicity of the SN-38-loaded poly(NIPA-co-DMAEMA) nanoparticles was investigated in human colon cancer cells (HT-29) to compare with the treatment of an anticancer drug, Irinotecan (CPT-11). The antitumor efficacy evaluated in a C26 murine colon tumor model showed that the SN-38-loaded nanoparticles in combination with hyperthermia therapy efficiently suppressed tumor growth. The results indicate that these thermo-responsive nanoparticles are potential carriers for controlled drug delivery. ? 2011 IOP Publishing Ltd.
SDGs
Other Subjects
Anti-cancer agents; Anti-tumor efficacy; Anticancer drug; Controlled drug release; Controlled release; Encapsulated drugs; Encapsulation efficiency; Ethyl methacrylates; Ethylmethacrylate; Human colon cancer cells; Irinotecan; Lower critical solution temperature; Release profiles; Release rate; Thermo sensitive; Thermo-responsive; Tumor growth; Tumor models; Volume phase transition; Acrylic monomers; Amides; Controlled drug delivery; Cytotoxicity; Drug products; Encapsulation; Free radical polymerization; Free radicals; Hyperthermia therapy; Tumors; Nanoparticles; 2-(dimethylamino)ethyl methacrylate; antineoplastic agent; camptothecin; drug derivative; irinotecan; methacrylic acid derivative; methacrylic acid dimethylaminoethyl ester; nanoparticle; poly(N isopropylacrylamide co ((2 dimethylamino)ethylmethacrylate)); poly(N-isopropylacrylamide-co-((2-dimethylamino)ethylmethacrylate)); polymethacrylic acid derivative; absorption; animal; article; Bagg albino mouse; cell death; cell strain HT29; chemistry; delayed release formulation; drug effect; endocytosis; female; fluorescence; human; methodology; mouse; nanotechnology; nuclear magnetic resonance spectroscopy; particle size; static electricity; temperature; thermogravimetry; ultrastructure; Absorption; Animals; Antineoplastic Agents; Camptothecin; Cell Death; Delayed-Action Preparations; Endocytosis; Female; Fluorescence; HT29 Cells; Humans; Magnetic Resonance Spectroscopy; Methacrylates; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotechnology; Particle Size; Polymethacrylic Acids; Static Electricity; Temperature; Thermogravimetry
Type
journal article